Welcome to our dedicated page for Innate Pharma Sa news (Ticker: IPHA), a resource for investors and traders seeking the latest updates and insights on Innate Pharma Sa stock.
Innate Pharma SA (IPHA) is a clinical-stage biotechnology leader advancing immuno-oncology therapies through innovative antibody development. This page serves as the definitive source for official company announcements and curated news coverage.
Key updates include clinical trial milestones, regulatory developments, strategic collaborations, and scientific advancements. Investors and researchers will find timely information on NK cell engager therapeutics, partnership expansions with major biopharma entities, and progress across the company's oncology pipeline.
All content is sourced directly from verified corporate communications and reputable financial analysis. Bookmark this page for streamlined access to IPHA's latest developments in harnessing innate immunity for cancer treatment breakthroughs.
Innate Pharma (Nasdaq: IPHA) has disclosed its latest share and voting rights data as of April 25, 2025. The company reported 92,175,723 ordinary shares outstanding, along with 6,494 Preferred Shares 2016 and 7,581 Preferred Shares 2017.
The total number of theoretical voting rights stands at 92,962,943, while exercisable voting rights amount to 92,944,368. The theoretical voting rights include those attached to AGAP 2016, comprising 130 voting rights for AGAP 2016-1 and 111 voting rights for AGAP 2016-2, while AGAP 2017 carries no voting rights.
Innate Pharma (IPHA) has announced a significant capital increase of €15 million through a strategic investment from Sanofi. The investment involves Sanofi subscribing to 8,345,387 new ordinary shares at €1.7974 per share, based on the volume-weighted average price on April 23, 2025.
The proceeds will be utilized for general corporate purposes, including extending the company's cash runway to support pipeline execution and long-term value creation. This investment builds upon their existing partnership, which includes the development of BCMA targeting ANKET® program in autoimmune indications.
Following the capital increase, Sanofi-Aventis Participations will hold a 9.05% stake in Innate Pharma, becoming one of the major shareholders alongside Novo Nordisk A/S (10.65%), Medimmune (8.12%), and Bpifrance Participations (6.93%).
Innate Pharma (IPHA) announces significant changes in its collaboration with Sanofi. The company will regain rights to CD123 targeting ANKET® SAR443579/IPH6101, currently in development for AML. The Phase 1/2 study showed promising results with 5 complete responses at 1 mg/kg and durable CR in 3 patients.
Sanofi plans a strategic investment of up to €15M in Innate through a capital increase, subject to market conditions. While Sanofi will discontinue BCMA targeting ANKET® (SAR'514/IPH6401) in multiple myeloma, it will redirect its development towards autoimmune indications.
The 2022 research collaboration agreement remains intact, with Sanofi maintaining rights to develop IPH62 (B7-H3 targeting program) and retaining an option for one additional ANKET® target. Innate remains eligible for over €1 billion in R&D and commercial milestones.
Innate Pharma (Nasdaq: IPHA) has announced plans to transform its corporate governance structure, proposing to shift from an executive board/supervisory board model to a CEO/board of directors structure at its Annual General Meeting on May 22, 2025.
Under the proposed changes, Irina Staatz-Granzer, current Supervisory board Chairwoman, would become Chairwoman of the board of Directors, while Jonathan Dickinson, current Executive board Chairman, would be appointed CEO. The new board would include eight members, with two new additions: Christian Itin, CEO of Autolus, and Marty J. Duvall, a veteran biotech executive.
Three current board members, including co-founder Hervé Brailly, Gilles Brisson, and Jean-Yves Blay, will not join the new board. This transformation aims to simplify governance and align with international standards, reflecting the company's response to investor feedback.
Innate Pharma (Nasdaq: IPHA) has announced its upcoming Annual General Meeting scheduled for May 22, 2025 at 10:30 a.m. CEST at their headquarters in Marseille, France. The meeting's Notice was published on April 16, 2025.
Key features of the AGM include:
- Live broadcast available online
- Guided laboratory tour for shareholders at 9:15 a.m. CEST
- Shareholders must register shares two business days prior to AGM
- Bearer shareholders need to obtain certificate of shareholding from brokers
- Written questions must be submitted four business days before the AGM
Innate Pharma (Nasdaq: IPHA) has announced its participation in the upcoming Stifel 2025 Virtual Targeted Oncology Forum, scheduled for April 8-9, 2025. The company's executive team will engage in two key activities during the event:
- Host one-on-one meetings with stakeholders
- Participate in a fireside chat on Wednesday, April 9, 2025, from 12:30 - 12:55 p.m. ET
The presentation will be accessible via live webcast and replay through the Events page in the Investors section of Innate Pharma's website.
Innate Pharma reported its 2024 financial results with several key developments. The FDA granted Breakthrough Therapy Designation to lacutamab for Sézary syndrome treatment. The company's first patient was dosed in Phase 1 study for IPH4502 (Nectin-4 ADC) in advanced solid tumors, and IPH6501 is being evaluated in B-cell non-Hodgkin's lymphoma.
Financial highlights include a cash position of €91.1 million as of December 31, 2024, with runway extended to mid-2026. Revenue decreased 67.4% to €20.1 million in 2024 (from €61.6 million in 2023). The Institute for Follicular Lymphoma Innovation (IFLI) announced up to $7.9 million investment to support IPH6501 development.
Notable pipeline progress includes positive data from the TELLOMAK Phase 2 study and advancement of the ANKET® platform programs. The company maintains strategic focus on NK-cell engager platform innovation and ADC program acceleration.
Innate Pharma (Nasdaq: IPHA) announced that an abstract for IPH4502, their novel topoisomerase I inhibitor Antibody Drug Conjugate (ADC) targeting Nectin-4, has been selected for presentation at the AACR Annual Meeting 2025 in Chicago.
IPH4502 is currently in Phase 1 clinical trials for advanced solid tumors. The drug has shown preclinical anti-tumor efficacy in models of primary and acquired resistance to enfortumab vedotin, as well as in tumors with low to moderate Nectin-4 expression, suggesting potential applications beyond urothelial carcinoma.
The presentation will take place during a poster session on Tuesday, April 29, 2025. Additionally, CEO Jonathan Dickinson will present an update on Innate's pipeline and strategy at the AACR Oncology Industry Partnering Event on April 24, 2025.
Innate Pharma (Nasdaq: IPHA) has announced its upcoming participation in the Life Sciences Van Lanschot Kempen Conference. The event is scheduled to take place in Amsterdam, Netherlands, from April 1-3, 2025. Members of the company's executive team will be attending this investor conference.
Innate Pharma (Nasdaq: IPHA) has scheduled a conference call and webcast to discuss its full year 2024 financial results on Thursday, March 27, 2025 at 2 p.m. CET / 9 a.m. EDT.
Key executives participating in the call will include Jonathan Dickinson (CEO), Sonia Quaratino (EVP, Chief Medical Officer), Yannis Morel (EVP, Chief Operating Officer), and Frédéric Lombard (SVP, Chief Financial Officer).
The webcast will be accessible through the company's website, with a replay available for 90 days following the event.
FAQ
What is the current stock price of Innate Pharma Sa (IPHA)?
What is the market cap of Innate Pharma Sa (IPHA)?
